-

Post Durnell Argument Scenario Statements – Attributable to Monsanto

LEVERKUSEN, Germany & ST. LOUIS--(BUSINESS WIRE)--“We appreciate the Court’s careful consideration of FIFRA’s Uniformity language and how its federal preemption provision applies to state-based label warnings.

“We believe the U.S. Government and the Company made persuasive arguments that state-based warning claims ‘in addition to or different from’ warning labels approved by EPA under FIFRA, as in Durnell, are preempted, and this is necessary to avoid a patchwork of 50 different warning labels. Companies should not be punished under state law for complying with federal label requirements. The security and affordability of the nation’s food supply depend on farmers’ and manufacturers’ ability to rely on the science-based judgments of federal regulators. A favorable ruling by the Supreme Court would provide essential regulatory clarity for companies who seek to bring currently approved and new products to market, addressing their ability to serve U.S. farmers and consumers.”

Contacts

Media Contact:
Brian Leake
(314) 370.3285

Monsanto


Release Versions

Contacts

Media Contact:
Brian Leake
(314) 370.3285

More News From Monsanto

Court Grants Final Approval to Roundup™ Class Settlement

ST. LOUIS--(BUSINESS WIRE)--Today, a Missouri state court granted final approval of the U.S. nationwide class settlement designed to resolve current and future Roundup™ claims alleging non-Hodgkin's lymphoma (NHL) injuries through a long-term claims program. The Court’s final approval order is subject to appeal. The class settlement, combined with the U.S. Supreme Court’s favorable ruling in June in the Durnell case, are mutually reinforcing pillars in the company’s multipronged strategy design...

Bayer’s SUNHARBO® (asundexian) Now Available in the United States

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that SUNHARBO® (asundexian), 50 mg tablets, is now available to order in the United States. Hospitals, health systems and pharmacies have immediate access to order the product for inventory. SUNHARBO is the first approved Factor XIa inhibitor in the U.S. and represents the first in a new class of medicine.1 SUNHARBO is indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic isc...

Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination With Antiplatelet Therapy Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicat...
Back to Newsroom